Special Import - Ozempic 0.25 Mg Prefilled Pen

Ozempic Prefilled Pen 0.25 Mg

Description:

Ozempic 0.25 mg pre-filled pen is a prescription diabetes medicine containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment and long-term management of type 2 diabetes mellitus in adults. It is supplied as a ready-to-use, once-weekly injectable solution in a prefilled pen designed for subcutaneous administration. Ozempic helps improve blood sugar control by enhancing glucose-dependent insulin secretion, reducing inappropriate glucagon release, and slowing gastric emptying, which together support better glycemic control and may contribute to weight reduction as part of a comprehensive diabetes care plan including diet and exercise.

Indications:

• Type 2 diabetes mellitus in adults, as an adjunct to diet and exercise to improve glycemic control.
• May be used as monotherapy when metformin is not tolerated or contraindicated, or in combination with other oral antidiabetic medicines or insulin as directed by a physician.
• Helps reduce elevated fasting and postprandial blood glucose levels.
• May support weight reduction in adults with type 2 diabetes when combined with lifestyle modifications (diet and physical activity), as guided by a healthcare professional.

Active Ingredients / Key Components:

• Semaglutide – 0.25 mg per dose (glucagon-like peptide-1 (GLP-1) receptor agonist).
• Other excipients (such as buffering agents, stabilizers, and water for injections) are present but specific names and concentrations , please check the product leaflet or the manufacturer’s official website.
• Concentration details beyond the stated 0.25 mg dose are not available in the provided data.

Dosage & Administration / How to Use:

• Ozempic 0.25 mg is typically used as a starting dose once weekly; it is not intended as a maintenance dose. The exact dosing schedule, titration, and maintenance dose must be determined by the prescribing physician.
• Administer by subcutaneous injection once weekly, on the same day each week, with or without food.
• Recommended injection sites: abdomen, thigh, or upper arm. Rotate injection sites with each dose to reduce the risk of lipodystrophy or skin irritation.
• Use the prefilled pen exactly as instructed in the patient leaflet or by your healthcare provider. Do not share the pen with others, even if the needle is changed.
• If a dose is missed, follow your doctor’s instructions or the official prescribing information for when to take the next dose. Do not double the dose to make up for a missed injection.
• Only use needles compatible with the Ozempic prefilled pen and always attach a new, sterile needle for each injection. Safely dispose of used needles in a sharps container.
• Do not use the pen if the solution appears cloudy, discolored, or contains particles. It should be clear and colorless.
• Always follow your doctor’s instructions regarding dose adjustments, especially when used in combination with insulin or sulfonylureas, to reduce the risk of hypoglycemia.

Clinical Benefits:

• Improves glycemic control in adults with type 2 diabetes by enhancing glucose-dependent insulin secretion and reducing inappropriate glucagon release.
• Helps lower fasting and post-meal blood sugar levels, supporting better long-term diabetes management and potentially reducing the risk of diabetes-related complications when used as prescribed.
• Once-weekly dosing improves treatment convenience and may enhance adherence compared with some daily injectable or oral therapies.
• Slows gastric emptying, which can help reduce appetite and caloric intake, potentially contributing to weight reduction as part of a comprehensive lifestyle program.

Warnings & Contraindications:

• Use only under the supervision of a qualified healthcare professional. Ozempic is a prescription medicine and is not suitable for self-initiation without medical advice.
• Contraindicated in patients with known hypersensitivity to semaglutide or any of the excipients.
• Not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis and should not be used as a substitute for insulin.
• Use with caution in patients with a history of pancreatitis; discontinue and seek medical attention if severe abdominal pain occurs that may radiate to the back.
• Use with caution in patients with severe gastrointestinal disease (e.g., severe gastroparesis), as GLP-1 receptor agonists slow gastric emptying.
• Monitor kidney function in patients with pre-existing renal impairment, especially if severe gastrointestinal side effects (nausea, vomiting, diarrhea) occur, as these may lead to dehydration and worsen renal function.
• May increase the risk of hypoglycemia when used in combination with insulin or insulin secretagogues (e.g., sulfonylureas); dose adjustments of concomitant therapy may be necessary.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Use during pregnancy or lactation should only occur if clearly needed and prescribed by a physician.
• Consult your doctor before use if you have liver disease, kidney disease, pancreatitis, diabetic retinopathy, gastrointestinal disorders, or other significant medical conditions.
• Do not drive or operate machinery if you experience dizziness, fatigue, or visual disturbances related to fluctuating blood glucose levels.
• Keep out of reach of children.

Side Effects:

• Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, indigestion, and fatigue. These are often mild to moderate and may decrease over time as the body adjusts to treatment.
• Other possible side effects include headache, dizziness, injection site reactions (redness, swelling, or itching), and mild increase in heart rate.
• Serious but less common side effects may include pancreatitis (severe, persistent abdominal pain that may radiate to the back, often with vomiting), severe allergic reactions (rash, itching, swelling of face/tongue/throat, difficulty breathing), and worsening of diabetic retinopathy in some patients with pre-existing eye disease.
• Hypoglycemia (low blood sugar) is more likely when Ozempic is used with insulin or sulfonylureas; symptoms include sweating, tremor, palpitations, hunger, confusion, or blurred vision. Seek immediate medical attention if severe hypoglycemia occurs.
• Stop using the product and contact your doctor or seek emergency medical care if you experience signs of a serious allergic reaction, pancreatitis, severe abdominal pain, or any other unusual or severe symptoms.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Product type: Prescription antidiabetic medicine (GLP-1 receptor agonist) in a prefilled injection pen.
• Strength: 0.25 mg semaglutide per dose (exact total volume and number of doses per pen , please check the product leaflet or the manufacturer’s official website).
• Form: Prefilled injectable solution in a pen device for subcutaneous use.
• Intended users: Adults with type 2 diabetes mellitus, as prescribed by a healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.